Clinical development of levetiracetam for amyotrophic lateral sclerosis

Drug News and Perspectives

Volumn 19, Issue 9, 2006, Pages 572-573

  Davies, S L ^a   Moral, M A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; MUSCLE CRAMP; NEUROPROTECTION; NONHUMAN; SHORT SURVEY; SPASTICITY;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS; HUMANS; MUSCLE CRAMP; MUSCLE SPASTICITY; NEUROPROTECTIVE AGENTS; PIRACETAM;

EID: 33846465857     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. Lukyanetz, E.A., Shkryl, V.M. and Kostyuk, P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002, 43: 9-18.
2. Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease (NCT00324454). ClinicalTrials.gov Web Site 2006, May 9.
3. Ross, B.H. and Thomas, C.K. Human motor unit activity during induced muscle cramp. Brain 1995, 118(Pt 4): 983-993.
4. Klitgaard, H., Matagne, A., Grimee, R., Vanneste-Goemaere, J. and Margineanu, D.G. Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy. Seizure 2003, 12: 92-100.
5. Niespodziany, I., Klitgaard, H. and Margineanu, D.G. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 2001, 306: 5-8.
6. Madeja, M., Margineanu, D.G., Gorji, A. et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel anti-epileptic mechanism of action? Neuropharmacology 2003, 45: 661-71.
7. Deleu, D. Levetiracetam in the treatment of idiopathic hemifacial spasm. Neurology 2004, 62: 2134-5.
8. Sheean, G. The pathophysiology of spasticity. Eur J Neurol 2002, 9 Suppl 1: 3-9.
9. Rigo, J.M., Hans, G., Nguyen, L. et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal. Br J Pharmacol 2002, 136: 659-72.
10. Hawker, K., Frohman, E. and Racke, M. Levetiracetam for phasic spasticity in multiple sclerosis. Arch Neurol 2003, 60: 1772-4.
11. Lipton, S.A. and Rosenberg, P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994, 330: 613-22.
12. Hanon, E. and Klitgaard, H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure 2001, 10: 287-93.
13. Marini, H., Costa, C., Passaniti, M. et al. Levetiracetam protects against kainic acid-induced toxicity. Life Sci 2004, 74: 1253-64.